These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39019717)

  • 21. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
    Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
    J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eyelash trichomegaly induced by erlotinib for metastatic lung cancer.
    Chan JYY; Kwok TYT; Yuen HKL
    Hong Kong Med J; 2021 Feb; 27(1):60.e1-60.e3. PubMed ID: 33568562
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.
    Hwang IG; Kang JH; Oh SY; Lee S; Kim SH; Song KH; Son C; Park MJ; Kang MH; Kim HG; Lee J; Park YS; Sun JM; Kim HJ; Kim CK; Yi SY; Jang JS; Park K; Kim HJ
    Support Care Cancer; 2016 Jan; 24(1):301-309. PubMed ID: 26041481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
    Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
    Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.
    Ruan Y; Jiang J; Guo L; Li Y; Huang H; Shen L; Luan M; Li M; Du H; Ma C; He L; Zhang X; Qin S
    Sci Rep; 2016 Mar; 6():23368. PubMed ID: 26988277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer.
    Cho SL; Lin WC; Chuang CA; Liao WY; Lai CF
    Nephrology (Carlton); 2020 Sep; 25(9):730. PubMed ID: 32364270
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
    Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
    Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erlotinib-Induced Transverse Fissure-Like Skin Lesions of Fingers.
    Sadeghi M; Loftus R; Dasanu CA
    Conn Med; 2016 Sep; 80(7):405-407. PubMed ID: 29782127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash.
    Lee WK; Myong J; Kwag E; Shin Y; Son JW; Yoo BC; Kim BS; Yoo HS; Choi JJ
    Integr Cancer Ther; 2023; 22():15347354231198090. PubMed ID: 37750513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repurposing calcium channel blockers: may be sensible combination with erlotinib for non-small cell lung cancer.
    Alandağ C; Merev E; Özdemir F
    Anticancer Drugs; 2021 Sep; 32(8):882-885. PubMed ID: 34145175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
    Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
    Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic study of erlotinib in a pregnant woman with advanced non-small cell lung cancer and observation of the effects on the child growth.
    Aida Y; Ohgami M; Mukai Y; Matsuyama M; Obata-Yasuoka M; Satoh T; Homma M; Sekine I; Hizawa N
    Br J Clin Pharmacol; 2024 Oct; 90(10):2554-2561. PubMed ID: 38889797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Zenke Y; Yoh K; Matsumoto S; Umemura S; Niho S; Ohmatsu H; Goto K; Ohe Y
    Clin Lung Cancer; 2016 Sep; 17(5):412-418. PubMed ID: 26944770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
    J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
    Monnet I; Audigier-Valette C; Girard N; Vergnenègre A; Molinier O; Souquet PJ; Blanchon F; Bonnetain F; Taguieva-Pioger N; Lamour C; Wislez M
    Lung Cancer; 2016 Aug; 98():84-90. PubMed ID: 27393512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
    Melosky B; Anderson H; Burkes RL; Chu Q; Hao D; Ho V; Ho C; Lam W; Lee CW; Leighl NB; Murray N; Sun S; Winston R; Laskin JJ
    J Clin Oncol; 2016 Mar; 34(8):810-5. PubMed ID: 26573073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.